Year: 2025
Type: article
Abstract: : Chronic migraine is a debilitating neurological disorder with a significant impact on patients' quality of life. This study aimed to evaluate the clinical efficacy and safety of botulinum toxin type A (onabotulinumtoxinA) as a preventive treatment for chronic migraine in a real-world clinical setting. Forty-eight patients diagnosed with chronic migraine received two treatment cycles of botulinum toxin according to the PREEMPT protocol. After 6 months, the average number of monthly headache days decreased by over 50%, with notable reductions in pain intensity, acute medication use, and migraine-related disability scores (MIDAS). The treatment was well-tolerated, with only minor and self-limiting side effects. These findings confirm that Botox is an effective and safe option for reducing the burden of chronic migraine and improving quality of life in affected individuals.
Institution: Samarkand State Medical Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4410157113